# A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

> **NCT04126044** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** PF-06439535 (CN)
- **DRUG:** bevacizumab - EU

## Key facts

- **NCT ID:** NCT04126044
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-22
- **Primary completion:** 2021-07-10
- **Final completion:** 2021-07-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn prior to enrollment after a comprehensive review of the biosimilars market and the company's global manufacturing network.
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126044, "A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04126044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*